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experienced a local recurrence at 5 months and 22 months, 
respectively (one of these patients developed a second local 
recurrence 3 years after the first recurrence). One patient 
developed a lung metastasis 17 months after diagnosis. All 
recurrent stage II patients were treated and are alive with no 
evidence of disease (NED). 
Of 41 stage III patients, a recurrence was experienced in 3 
patients (7%). All of these recurrences were in the lung and 
were experienced at 4 months, 5 months, and 7 months after 
diagnosis. 
One out of eleven patients (9%) with stage IV disease 
experienced a recurrence. This was a local recurrence 
experienced 4 months after diagnosis. None of the 8 patients 
with stage V disease experienced a recurrence. Risk of 
progression based on stage is shown in the table below. 
The median time to failure was 6 months from diagnosis. Of 
the eight total recurrences (including 2 local recurrences in a 
single patient), 6 were salvaged and currently have no 
evidence of disease. Two patients are alive with active 
disease. 
Progression-free survival was 89%. Sixty three of the 64 
patients are still alive, giving an overall survival of 98.4%. 
The single patient who died had stage IV disease at diagnosis 
and experienced a recurrence prior to death. 
 
Stage PFS (%) OS (%) 
I 100 100 
II 80 100 
III 93 100 
IV 91 91 
V 100 100 
 
 
 
Conclusions: Children with Wilms tumor can have excellent 
long-term outcomes when managed per NWTS/COG 
protocols. After 11 years of median follow up, PFS and OS 
were both excellent at 89% and 98.4%, respectively. 
   
PO-0759   
Modern radiotherapy improves survival in paediatric 
patients with Ewing sarcoma 
V. Granados Prieto1, J.L. Lopez Guerra2, C. Marquez1, G. 
Ramirez1, P. Cabrera2, J.M. Praena-Fernandez3, M.J. Ortiz 
Gordillo2 
1University Hospital Virgen Del Rocio, Paediatric oncology, 
Sevilla, Spain  
2University Hospital Virgen Del Rocio, Radiation oncology, 
Sevilla, Spain  
3University Hospital Virgen Del Rocio, Methodology Unit- 
Fundación Pública Andaluza para la Gestión de la 
Investigación en Salud de Sevilla, Sevilla, Spain  
 
Purpose/Objective: To analyze the epidemiological 
characteristics of paediatric patients with Ewing's Sarcoma 
(ES) and assess the outcome (overall survival [OS] and disease 
free survival [DFS]) as well as potential prognostic factors 
associated with survival after the multidisciplinary 
treatment.  
Materials and Methods: Retrospective study of paediatric 
patients with ES treated during the period 1979-2014. SPSS 
19.0 was used for statistical analysis and Kaplan-Meier's 
method for the analysis of survival. The potential risk factors 
were assessed using univariate and multivariate analyses. 
Results: During the last 35 years, 102 patients were treated 
at our Institution. Male patients were 55.8% and the median 
age was 10.5 years (range 2-19). The pain was the most 
common symptom at initial presentation. Non-axial location 
was observed in 62.8% of patients and non-metastatic or 
multicentric disease in 83.3%. The median time between the 
onset of symptoms and the date of diagnosis was 3.07 months 
(range: 0.1- 36.5 months). 68.7% received surgery, 49% 
radiotherapy (with radical intention, before or after surgery) 
and 25.5 % hematopoietic stem cell transplantation. The 2 
and 5-years OS was 81 % and 57 %, respectively. Two and five 
years DFS was 68% and 54%, respectively. Local recurrence 
occurred in 11.8 % and distant relapse in 36.2 % of patients. 
Secondary malignancies occurred in 5% of patients (2 acute 
myeloblastic leukemia, 2 myelodysplastic syndromes and one 
pleomorphic sarcoma). Risk factors for OS observed in the 
univariate analysis were: an erythrocyte sedimentation rate 
at diagnosis > median (Median 43; HR: 4.42, p = 0.02), the 
lack of surgery (HR 1.97, p = 0.024), poor pathological 
responder (> 10% viable tumor) to induction chemotherapy 
(HR 2.88, p = 0.012), the use of cobalt units vs. linear 
accelerators (HR 2.93, p = 0.009) and the response to 
multidisciplinary treatment (progression versus rest of 
responses; HR 6.52, p <0.001). In multivariate analysis only 
the radiotherapy units (HR 4,21, p = 0,030) and the response 
to treatment (Response vs progression: HR 0,10, p < 0,001) 
retained statistically significance. 
Conclusions: Our results suggest that paediatric patients with 
ES who have a good response to the multidisciplinary 
treatment or those treated with linear accelerators vs cobalt 
units have a lower risk of mortality. Therefore, it seems that 
technological development has contributed to improve the 
survival in these patients.  
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